77960-22-6

Usage

Uses

Used in Pharmaceutical Industry:
4-OXO-3-PHENETHYL-10-OXA-3-AZA-TRICYCLO[5.2.1.0(1,5)]DEC-8-ENE-6-CARBOXYLIC ACID is used as a pharmaceutical compound for its potential biological activities. Its structural complexities and diverse functional groups may contribute to the development of new drugs with unique mechanisms of action.
Used in Agrochemical Industry:
In the agrochemical industry, 4-OXO-3-PHENETHYL-10-OXA-3-AZA-TRICYCLO[5.2.1.0(1,5)]DEC-8-ENE-6-CARBOXYLIC ACID is used as a potential active ingredient in the development of new pesticides or herbicides. Its unique chemical properties may offer novel modes of action for controlling pests and weeds.
Used in Materials Science:
4-OXO-3-PHENETHYL-10-OXA-3-AZA-TRICYCLO[5.2.1.0(1,5)]DEC-8-ENE-6-CARBOXYLIC ACID is utilized in materials science for its potential to contribute to the development of new materials with unique properties. Its structural features and functional groups may be harnessed to create innovative materials with applications in various industries.

InChI:InChI=1/C17H17NO4/c19-15-14-13(16(20)21)12-6-8-17(14,22-12)10-18(15)9-7-11-4-2-1-3-5-11/h1-6,8,12-14H,7,9-10H2,(H,20,21)/p-1/t12-,13+,14-,17+/m1/s1

Upstream product

• 108-31-6 maleic anhydride 
• 4439-55-8 N-(furan-2-ylmethyl)-2-phenylethan-1-amine 
• 98-01-1 furfural 
• 64-04-0 phenethylamine 
• 69819-53-0 N-(2-furylmethylidene)-2-phenylethylamine 

Downstream Products

• 943251-45-4 3-oxo-2-phenethyl-2,3-dihydro-1H-isoindole-5-carboxylic acid 

Relevant academic research and scientific papers

Discovery of 2-[1-(4,4-Difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide (NMS-P118): A Potent, Orally Available, and Highly Selective PARP-1 Inhibitor for Cancer Therapy

The nuclear protein poly(ADP-ribose) polymerase-1 (PARP-1) has a well-established role in the signaling and repair of DNA and is a prominent target in oncology, as testified by the number of candidates in clinical testing that unselectively target both PARP-1 and its closest isoform PARP-2. The goal of our program was to find a PARP-1 selective inhibitor that would potentially mitigate toxicities arising from cross-inhibition of PARP-2. Thus, an HTS campaign on the proprietary Nerviano Medical Sciences (NMS) chemical collection, followed by SAR optimization, allowed us to discover 2-[1-(4,4-difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide (NMS-P118, 20by). NMS-P118 proved to be a potent, orally available, and highly selective PARP-1 inhibitor endowed with excellent ADME and pharmacokinetic profiles and high efficacy in vivo both as a single agent and in combination with Temozolomide in MDA-MB-436 and Capan-1 xenograft models, respectively. Cocrystal structures of 20by with both PARP-1 and PARP-2 catalytic domain proteins allowed rationalization of the observed selectivity.

Synthesis of advanced intermediates of lennoxamine analogues

A simple and convenient method for synthesis of advanced isoindolone intermediates of lennoxamine and analogues is described in this paper. The intramolecular Diels-Alder reaction of furan is used as a key step in this synthesis. Georg Thieme Verlag Stuttgart.